2MOK T S, WU Y L, THONGPRASERT S, et al. Gefitinib or carboplatin-paclitaxel in puhnonary adenocarcinoma [ J ] N Engl J Med, 2009, 361(10): 947-957.
3WU Y L, ZHOU C, HU C P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial [J]. Lancet Oncol, 2014, 15(2): 213-222.
4ZHOU C, WU Y L, CHEN G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a muhicentre, open-label, randomised, phase 3 study[J].Lancet Oncol, 201 I, 12(8): 735-742.
5MICHAEL M, WHITE S C, ABDI E, et al. Multicenter randomized, open-label phase H trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC [ J ]. Asia Pac J Clin Oncol, 2014, 11(1): 4-14.
6DITTRICH C, PAPAI-SZEKELY Z, VINOLAS N, et al. A randomised phase 1~ study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer [J]. Cur J Cancer, 2014, 50(9): 1571-1580.
7AULIAC J B, CHOUAID C, GREILLER L, et al. Randomized open-label non-comparative muhicenter phase ]I trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first- line chemotherapy: GFPC 10. 02 study [ J ] . Lung Cancer, 2014, 85(3): 415-419.
8WU Y L, LEE J S, THONGPRASERT S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, donble-blind trial [ J ~ . Lancet Oncol, 2013, 14(8): 777-786.
9LEE D H, LEE J S, KIM S W, et al. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer [ J ] . Eur J Cancer, 2013, 49(15): 3111- 3121.
10FELD R, SRIDHAR S S, SHEPHERD F A, et al. Use of the epidermal growth factor receptor inhibitors gefitinib and er|otinib in the treatment of non-sinai| cell lung cancer: a systematic review [ J 1 ~ J Thorac Oncol, 2006, 1(4): 367- 376.
